Italy In-Vitro Diagnostics Market Forecast Report by Test Types Products Technology Application End User and Company Analysis, 2024-2032

Italy In-Vitro Diagnostics Market Analysis

Italy In-Vitro Diagnostics Market was US$ 2.61 Billion in 2023 and will grow US$ 4.67 Billion by 2032, with a CAGR of 6.68% from 2024 to 2032. Growth is also anticipated to be fueled by the nation's growing chronic disease prevalence and the significant investments made in R&D by industry leaders to create cutting-edge technologies for investigating novel approaches to disease detection. Italy is predicted to see a rise in the prevalence of a number of diseases, including cancer, autoimmune disorders, myocardial infarctions, arrhythmias, and inflammatory ailments, which will drive up demand for IVD testing.

Italy In-Vitro Diagnostics Market Overview

The term "in-vitro diagnostics" (IVD) describes a broad range of medical procedures used to diagnose illnesses, track the effectiveness of treatment, and evaluate general health status using samples of human fluids, tissues, or cells that are kept outside of the body. Numerous methods and tools, such as immunoassays, molecular diagnostics, clinical chemistry, hematology, and microbiology, are used to conduct these tests in laboratory settings. These tests make it possible to identify illnesses early, which enables prompt intervention and the start of therapy. IVD testing provide personalized medicine by facilitating quick and precise results that inform customized treatment plans based on unique patient features. Additionally, by offering insightful knowledge about biological systems, in-vitro trials help researchers and scientists advance areas like pharmacology, biotechnology, and medicine. They are vital resources for comprehending basic biological processes and creating novel approaches to health problems.

The increasing occurrence of chronic illnesses is a major driver propelling the market's expansion. The need for early diagnosis utilizing IVD devices is rising due to the number of patients with various infectious and chronic diseases. As a result, more people are using in-vitro diagnostics for a variety of ailments. For example, a December 2022 report published by Nova Agency indicated that 390,700 new cases of cancer were expected in Italy year 2022. In a similar vein, the International Diabetes Federation (IDF) estimates that 4.47 million Italians suffered from diabetes in 2021 and that number is expected to rise to 4.59 million by 2045. As a result, the high prevalence of disease among Italians is fueling the nation's adoption of in-vitro diagnostic instruments and raising the demand for early disease diagnosis.

Growth Factors in the Italy In-Vitro Diagnostics Industry

Growth in the In-Vitro Diagnostics Market is Driven by Increasing Healthcare Spending in Italy

The in-vitro diagnostics business in Italy is expanding thanks in large part to the notable rise in healthcare spending. Italy has made large investments in healthcare, amounting to USD 4291 per capita and accounting for 9.0% of its GDP, as per an OECD assessment. This indicates a strong commitment to improving healthcare infrastructure and services. This large donation encourages advancements in patient care delivery by enabling healthcare providers to use cutting-edge diagnostic tools and creative solutions.

Information and Communications Technology (ICT) Integration in Healthcare Fuels Market Expansion

The growing in-vitro diagnostics business in Italy is mostly being driven by the integration of Information and Communications Technology (ICT) in healthcare. With a 7% rise from 2021 to 2022, Italy spent USD 1.98 billion on ICT for healthcare. Healthcare diagnostic processes can be made more accurate and efficient by leveraging digital tools like data analytics, telemedicine platforms, and electronic health records. ICT facilitates easy communication between labs, medical professionals, and patients, allowing for the early diagnosis of illnesses and the modification of treatment plans as necessary. ICT developments also make it possible to remotely monitor patients' health problems, which allows for quick intervention and the application of preventive healthcare measures.

Italy In-Vitro Diagnostics Market Company Overview

Some of the industry leaders seen in the Italy In-Vitro Diagnostics Market Includes Roche Diagnostics, Abbott Diagnostics, Siemens Healthineers, Danaher Corporation, Thermo Fisher Scientific, Sysmex Corporation.

Italy In-Vitro Diagnostics Market News

In April 2023, in order to commercialize the DiviTum TKa test in Italy, Biovica International and IT Health Fusion entered into a business cooperation. Thymidine kinase activity (TKa) in human serum is measured semi-quantitatively using this in-vitro diagnostic instrument.

In May 2022, Italy implemented the new EU In Vitro Diagnostic Regulation (EU) 2017/746 (IVDR) on May 26, 2022. While some legacy devices will benefit from transitional periods, the IVDR criteria now apply to all new IVDs as well as those low-risk IVDs that are already marketed.

Test Types - Market breakup in 11 viewpoints:

1. ELISA & CLIA

2. PCR

3. Rapid Test

4. Fluorescence Immunoassays (FIA)

5. In Situ Hybridization

6. Transcription Mediated Amplification

7. Sequencing

8. Colorimetric Immunoassay

9. Radioimmunoassay (RIA)

10. Isothermal Nucleic Acid Amplification Technology

11. Others

Products - Market breakup in 3 viewpoints:

1. Services

2. Instruments

3. Reagents

Technology - Market breakup in 7 viewpoints:

1. Immunoassay

2. Clinical Chemistry

3. Molecular Diagnostics/Genetics

4. Hematology

5. Microbiology

6. Coagulation

7. Others

Application - Market breakup in 8 viewpoints:

1. Infectious Disease

2. Diabetes

3. Cardiology

4. Oncology

5. Nephrology

6. Autoimmune Diseases

7. Drug Testing

8. Other Applications

End User - Market breakup in 4 viewpoints:

1. Hospitals

2. Laboratories

3. Home - Care

4. Others

All the Key players have been covered from 5 Viewpoints:

• Overviews
• Key Person
• Recent Developments & Strategies
• Product Portfolio & Product Launch in Last 1 Year
• Revenue

Company Analysis:

1. Roche Diagnostics

2. Abbott Diagnostics

3. Siemens Healthineers

4. Danaher Corporation

5. Thermo Fisher Scientific

6. Sysmex Corporation